Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is Gentium's Upside Really This Juicy?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of Gentium (UNKNOWN: GENTY.DL  ) opened Monday up 5% after Wedbush raised its price target on the small-cap biotechnology stock.

So what: Webush maintained its "outperform" rating on Gentium, but the new price target of $35 per share (all the way from $20) represents about 40% worth of upside to its closing price on Friday. The stock soared back in July after the CHMP reversed its negative opinion on Gentium's hepatic veno-occlusive disease treatment Defitelio, but analyst David Nierengarten still sees plenty of upside in the shares as the drug gains regulatory momentum.

Now what: I'd expect the stock to remain hot in the short term.

"We anticipate that a significant (20%+) price increase ... could occur upon official approval; with changes in reimbursement by central European authorities put in place over the 2 quarters following approval," said Nierengarten. "We note that in certain countries (Germany, Italy and the UK) reimbursement decisions are made in a shorter timeframe."

Of course, with the stock now up a whopping 280% over its 52-week lows and trading at a forward P/E of 30, I'd wait for a wider margin of safety before making a longer commitment. 

More compelling health care picks
Obamacare is rewriting the rules for the health care industry, and in the process of doing so, it's creating massive opportunities for investors to get ridiculously rich. How? By investing in a handful of specific health care stocks. In this free report, our analysts walk you through these opportunities and the companies that are positioned to exploit them. The informational edge contained in it is invaluable, but can only be exploited profitably while the rest of the market remains in the dark. To access this free report instantly, simply click here now.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2660622, ~/Articles/ArticleHandler.aspx, 9/26/2016 11:57:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,118.69 -142.76 -0.78%
S&P 500 2,150.53 -14.16 -0.65%
NASD 5,266.44 -39.31 -0.74%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
GENTY.DL $0.00 Down +0.00 +0.00%
Gentium S.p.A. (AD… CAPS Rating: **